research use only

(−)-Norepinephrine Adrenergic Receptor agonist

Name: (−)-Norepinephrine
Brand: Selleck Chemicals
SKU: S9507
Availability: InStock
Rating: 5 (13 reviews)

Cat.No.S9507

(−)-Norepinephrine (Arterenol, Levarterenol, L-Noradrenaline) is a natural neurotransmitter and hormone. It is an agonist of adrenergic receptors with Ki values of 330, 56, and 740 nM for α1, α2, and β1 adrenoceptors, respectively.This compound can be used to induce animal models of Cardiomyopathy.

Chemical Structure

Molecular Weight: 169.18

Jump to

Quality Control

Batch: Purity: 99.64%

99.64

Related Targets	AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other Adrenergic Receptor Inhibitors	ICI 118551 Hydrochloride (Zenidolol) L755507 Yohimbine HCl Atipamezole Higenamine hydrochloride Noradrenaline bitartrate monohydrate Fenoterol hydrobromide Medetomidine HCl Isoprenaline L-Adrenaline

Solubility

In vitro
Batch:

DMSO : 3 mg/mL (17.73 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.550mg/ml (3.25mM)	Taking the 1 mL working solution as an example, add 50 μL of 11 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.550mg/ml (3.25mM)	Taking the 1 mL working solution as an example, add 50 μL of 11 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	169.18	Formula	C₈H₁₁NO₃	Storage (From the date of receipt)	3 years -20°C(in the dark) powder 1 year -80°C(in the dark) in solvent
CAS No.	51-41-2	--		Storage of Stock Solutions	Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt.

Read more about storage stability CAS number

Mechanism of Action

Targets/IC₅₀/Ki	α2A adrenoceptor (CHO-C10 cells) 56 nM(Ki) α1 adrenoceptor (cell-based assay) 330 nM(Ki) β1 adrenoceptor (cell-based assay) 740 nM(Ki)
In vitro	(-)-Norepinephrine inhibits the production of TNF-α, IL-6, and CXCL2/MIP-2 and promotes the secretion of IL-10 from LPS-stimulated murine alveolar macrophages. This compound down-regulates NF-κB activation in stimulated alveolar macrophages.
In vivo	Injection of (-)-Norepinephrine into senescence-accelerated prone 8 (SAMP8) mice reverses formaldehyde accumulation and this compound deficiency and restored the magnitude of long-term potentiation and memory.
References	[1] https://pubmed.ncbi.nlm.nih.gov/17303246/ [2] https://pubmed.ncbi.nlm.nih.gov/32643759/ [3] https://pubmed.ncbi.nlm.nih.gov/25866202/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-05-01)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07562932	NOT_YET_RECRUITING	Cardiogenic Shock	Chonnam National University Hospital	2026-05-31
NCT07363109	NOT_YET_RECRUITING	Hypotension After Spinal Anesthesia; Hypotension During Cesarean Delivery	Aretaieion University Hospital	2026-02
NCT07063680	RECRUITING	Patients With Norepinephrine-refractory Vasoplegic Shock	Centre Hospitalier Universitaire Dijon	2026-04-07	PHASE3
NCT07667829	NOT_YET_RECRUITING	Pulmonary Arterial Hypertension (PAH); Chronic Thromboembolic Pulmonary Hypertension (CTEPH); Hypertension, Pulmonary	China National Center for Cardiovascular Diseases	2026-06
NCT06746753	NOT_YET_RECRUITING	Septic Shock	Wake Forest University Health Sciences	2026-09	PHASE4
NCT06802224	RECRUITING	Anesthesia; Surgery With General Anesthesia; Noncardiac Surgery; Hypotension During Surgery; Acute Kidney Injury (AKI); Myocardial Injury After Noncardiac Surgery (MINS); Vasopressor	University of California, San Francisco	2025-04-01	PHASE4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):